Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
NCT ID: NCT00749021
Last Updated: 2012-10-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
40 participants
INTERVENTIONAL
2008-09-30
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Regimen 1
Intravitreal injection of Ranibizumab monthly for 12 months.
Ranibizumab
0.5 mg of intravitreal ranibizumab monthly for 12 months
Regimen 2
Intravitreal injection of ranibizumab for 4 months (at Day 0, Month 1, Month 2, and Month 3) followed by by treatments on predefined re-treatment criteria.
Ranibizumab
0.5 mg intravitreal injection of ranibizumab for 4 months followed by PRN dosing
Regimen 3
Intravitreal injection of Ranibizumab 2.0mg monthly for 12 months
Ranibizumab
2.0mg of intravitreal ranibizumab monthly for 12 months
Regimen 4
Intravitreal injection 2.0mg ranibizumab for 4 months (at Day 0, Month 1 and Month 2, and Month 3) followed by PRN treatments on pre-defined re-treatment criteria
Ranibizumab
2.0mg of intravitreal injection of Ranibizumab for 4 months followed by PRN dosing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ranibizumab
0.5 mg of intravitreal ranibizumab monthly for 12 months
Ranibizumab
0.5 mg intravitreal injection of ranibizumab for 4 months followed by PRN dosing
Ranibizumab
2.0mg of intravitreal ranibizumab monthly for 12 months
Ranibizumab
2.0mg of intravitreal injection of Ranibizumab for 4 months followed by PRN dosing
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient is willing to participate in this study and to follow the criteria and protocol of this study.
* Patient is not involved with another clinical trial.
* Ability to understand the informed consent and willingness to sign the consent.
* Presence of a submacular vascularized or fibrovascular PED. Central foveal involvement by the PED or the CNV due to age related macular degeneration.
* PED less than or equal to 12 disc area in size
* BCVA with ETDRS of greater than or equal to 19 letters and less than or equal to 69 letters (20/400 to 20/40)
* Central 1-mm foveal thickness of greater than or equal to 250 microns on OCT.
* Greatest linear diameter of the submacular hemorrhage needs to be less than 50% of the entire PED.
* Submacular fibrosis needs to be less than 50% of the entire PED.
* Sufficiently clear media (cornea, anterior chamber, lens, vitreous) for OCT, FA, and FP.
* Intraocular pressure of 25 mm or less in the study eye, with or without use of ocular hypotensive agents.
Exclusion Criteria
* Premenopausal women not using adequate contraception
* Known serious allergies to ranibizumab, fluorescein dye, drug for pupillary dilation, topical anesthetic, sterilizing solution
* Contraindication to pupillary dilation in study eye
* Any condition (including inability to read visual acuity charts or language barrier) that may preclude patient's ability to comply with the study protocol requirements
* Presence of any advanced systemic condition or endstage disease, advanced Alzheimer syndrome, endstage cancer, etc., which will likely prevent patient from completing study.
* Previous therapeutic radiation in the region of the study eye.
* Prior anti-vascular endothelial factor therapy within 30 days.
* More than 3 sessions of prior anti-VEGF therapy.
* More than 1 prior photodynamic therapy (PDT)
* Prior triamcinolone in the past 6 months or dexamethasone in the past 1 month.
* Prior retinal pigment epithelial (RPE) tear in study eye.
* Prior ocular surgery (except YAG laser capsulotomy) for study eye within past 90 days.
* Anticipated ocular surgery (except YAG laser capsulotomy) for the next 12 months.
* Prior therapy for AMD (except minerals and vitamins), including laser, within the past 30 days.
* Prior intraocular or periocular corticosteroid therapy within the past 120 days
* Prior vitrectomy
* Presence of any causes of CNV and PED other than due to AMD.
* Presence of any substantial ocular disease (other than CNV and PED) that may compromise vision in the study eye and/or confound interpretation of the date; e.g. substantial cataracts, concomitant diabetic retinopathy affecting the macula, advanced glaucoma, optic neuritis, optic neuropathy or atrophy, marked macular atrophy, ocular vascular occlusion, history of retinal detachment, uveitis, viral or other forms of chorioretinitis, etc.
* Presence of ocular disease other than AMD affecting study eye, i.e. presumed ocular histoplasmosis syndrome, angioid streaks, pathologic myopia (spherical equivalent of greater than or equal to -8 diopters of myopia or axial length of greater than or equal to 25 mm), choroidal rupture, multifocal choroiditis, etc.
* Active ocular infection (i.e., bacterial, viral, parasitic, or fungal) in either eye at screening or Day 0.
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clement K. Chan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Clement K. Chan
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clement K Chan, M.D.
Role: PRINCIPAL_INVESTIGATOR
Southern California Desert Retina Consultants
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jules Stein Eye Institute
Los Angeles, California, United States
Southern California Desert Retina Consultants
Palm Desert, California, United States
Black Hills Regional Eye Institute
Rapid City, South Dakota, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Chan CK, Abraham P, Sarraf D, Nuthi AS, Lin SG, McCannel CA. Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration. Eye (Lond). 2015 Jan;29(1):80-7. doi: 10.1038/eye.2014.233. Epub 2014 Oct 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FVF4332s
Identifier Type: -
Identifier Source: org_study_id